AC
UNCY icon

Ayrton Capital’s Unicycive Therapeutics UNCY Stock Holding History

Ayrton Capital’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,665
Closed -$45K – 104
2022
Q3 		$45K Hold
7,665
– – 0.08% 50
2022
Q2 		$64K Hold
7,665
– – 0.1% 48
2022
Q1 		$99K Hold
7,665
– – 0.13% 60
2021
Q4 		$158K Buy
+7,665
New +$192K 0.15% 64

Other funds holding UNCY

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tandem Capital Management Woodcliff Lake, New Jersey $200M AUM 25.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Ayrton Capital's UNCY Position: Q4 2022 in Review

Ayrton Capital sold out of Unicycive Therapeutics (UNCY) in Q4 2022, closing a stake of 7,665 shares — an estimated $45K sold.

Ayrton Capital first reported a position in UNCY in Q4 2021 and held it in 4 quarters. The position peaked at $158K in Q4 2021. 9 funds tracked by Wall St. Rank hold UNCY as of Q4 2022.

  • Ayrton Capital reported no remaining Unicycive Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Ayrton Capital sold 7,665 Unicycive Therapeutics shares in Q4 2022, an estimated $45K.
  • Ayrton Capital first reported a position in Unicycive Therapeutics in Q4 2021 and held it in 4 quarters.
  • Ayrton Capital's Unicycive Therapeutics position peaked at $158K in Q4 2021.
  • 9 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q4 2022.

Based on Ayrton Capital's 13F filing for Q4 2022, filed 14 Feb 2023.